The Need for a Slow Taper of Weight Loss Medication Tapering off GLP-1 medications slowly is crucial
And more deeply, whether we're still ignoring the societal reasons that lead to obesity
Cancer Sci 103:760766 Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, Padda SK, Ramchandran K, Neal JW, Wakelee H, Diehn M (2020) Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of patients with non-small cell lung cancer
This almost always indicates bacterial or fungal growth
One difference between EMPA-REG OUTCOME and the CANVAS Program is the significant reduction in CV and all-cause mortality with empagliflozin, both of which were not observed in the CANVAS Program (5,8)
Tracking your progress goes hand-in-hand with the gradual dose adjustments you made in the previous step